Schizophrenia Evaluation & Medication Management

Schizophrenia Evaluation & Medication Management

Schizophrenia is highly responsive to early intervention. The period immediately following first-episode psychosis represents a critical window where treatment dramatically improves long-term outcomes. At KwikPsych in Austin, Dr. Monika Thangada, MD, provides expert evaluation and management of first-episode and established schizophrenia.

Why Early Intervention Matters

The duration of untreated psychosis (DUP)—time between symptom onset and treatment initiation—profoundly affects prognosis:

Research shows:

• Shorter DUP associated with better treatment response
• Better long-term functioning and prognosis
• Reduced cumulative brain stress from active psychosis
• Greater likelihood of returning to work/school
• Better symptom remission rates
• Reduced risk of chronic functional impairment

DUP typically ranges:

• Average 1-3 years (concerning delay)
• Shorter in developed healthcare systems
• Affected by awareness, access, stigma
• Every month of untreated psychosis matters

Early identification and treatment is therefore critical.

Comprehensive Schizophrenia Evaluation

Clinical Interview

Psychotic symptom details:

• When did symptoms start?
• What are the hallucinations? (Content, frequency, distress level)
• What are the beliefs? (Delusions—false fixed beliefs)
• How long present? (Timeline critical for diagnosis)
• How much distress causing?
• How much interference with functioning?
• Any danger/safety risk from symptoms?

Onset and prodrome:

• Were there warning signs preceding psychosis?
• Declining performance
• Social withdrawal
• Sleep disruption
• Concentration difficulty
• Suspiciousness
• What triggered onset? (Stressor, sleep loss, substance use)
• Acute vs. gradual emergence?

Functioning assessment:

• School/work impact
• Relationship impact
• Self-care and hygiene
• Safety concerns (self-injury, harm to others)
• How different from baseline?

Prior mental health:

• Any prior mood episodes (depression, mania)?
• Anxiety history?
• Behavioral issues?
• Psychiatric medication trials?
• Hospitalization history?

Substance use (critical):

• Cannabis use? Frequency, age of onset
• Stimulants (methamphetamine, cocaine, amphetamine)?
• Alcohol use pattern?
• Other drugs?
• Substances can cause psychosis—must differentiate

Family psychiatric history:

• Anyone with schizophrenia or psychosis?
• Bipolar disorder?
• Depression?
• Substance use disorders?
• Age of onset in relatives?
• Response to medications?

Medical history:

• Any seizures or neurological condition?
• Head injury or trauma?
• Infections (especially CNS)?
• Chronic illness?
• Medications and supplements (some can cause psychosis)?

Mental Status Examination

Appearance:

• Grooming and hygiene
• Dress appropriateness
• Age appearance
• Any unusual appearance features

Behavior:

• Psychomotor activity (normal, retarded, agitated)
• Purposefulness of movements
• Bizarre behaviors?
• Catatonic features? (waxy flexibility, mutism, posturing)

Speech:

• Rate and rhythm
• Organization (coherent, tangential, circumstantial, incoherent)
• Any echolalia or neologisms?
• Poverty of speech?

Mood/Affect:

• Self-reported mood
• Observed affect (flat, congruent with mood, appropriate)
• Stability during interview
• Any perplexity or fear?

Thought process and content:

• Organization (logical, loose associations)
• Delusions present? (Content, conviction, preoccupation)
• Hallucinations present? (Modality, content, frequency)
• Magical thinking or ideas of reference?
• Obsessions or compulsions?
• Homicidal/suicidal ideation?

Perception:

• Any hallucinations acknowledged?
• Any illusions?
• Insight into experiences? (Recognize as unusual)

Cognition:

• Orientation (person, place, time)
• Attention and concentration
• Memory (registration, retention, recall)
• Abstract thinking
• Calculation ability

Insight and judgment:

• Understands has psychiatric illness?
• Understands needs treatment?
• Understanding of consequences?
• Judgment about decisions?

Medical Evaluation

Physical examination:

• Vital signs
• General examination
• Neurological examination (reflexes, strength, gait, coordination)
• Screen for medical conditions

Laboratory assessment:

Essential labs:

• Complete blood count (CBC): Baseline for antipsychotic monitoring
• Comprehensive metabolic panel: Glucose, kidney function, liver function, electrolytes
• Thyroid function (TSH, free T4): Hypothyroidism can mimic depression; hyperthyroidism can mimic anxiety
• Lipid panel: Baseline for medication-induced metabolic effects
• Prolactin level: Baseline for dopamine antagonist effects
• Substance screen (urine drug screen): Rule out drug-induced psychosis

Consider based on history:

• Syphilis serology: If any risk factors
• HIV test: If any risk factors
• EBV or other infectious serology: If relevant history

Imaging considerations:

• CT or MRI brain: To rule out structural causes (tumor, stroke, trauma)
• Generally obtained for first-episode psychosis
• Essential if focal neurological signs
• Important for diagnostic clarity
• Structural causes rare but important not to miss

EKG:

• Baseline assessment
• Important if family history of cardiac issues
• Critical before certain antipsychotics (risperidone, quetiapine, clozapine)

Structured Assessment Tools

Positive and Negative Symptom Scale (PANSS):

• 30-item scale assessing positive, negative, general psychopathology symptoms
• Scores: 30-210 (higher = worse)
• Standardized assessment
• Useful for monitoring treatment response
• Gold standard for research; useful clinically

Brief Psychiatric Rating Scale (BPRS):

• 18 items assessing psychiatric symptoms
• Quick assessment tool
• Useful for monitoring changes

Clinical Global Impression (CGI):

• Single-item severity rating
• Useful for tracking treatment response

Scales for specific domains:

• Calgary Depression Scale: Depression in schizophrenia
• Scale for Assessment of Negative Symptoms (SANS)
• Scale for Assessment of Positive Symptoms (SAPS)

Differential Diagnosis

Schizophrenia vs. Other Conditions

Substance-induced psychosis:

• Resolves after substance cessation
• Timeline: Recent use preceding psychosis
• Cannabis, stimulants, hallucinogens, alcohol withdraw common causes
• Drug screening critical

Brief psychotic disorder:

• Psychotic symptoms 1 day to 1 month duration
• Often stressor-related
• Better prognosis
• Different diagnostic criteria

Schizophreniform disorder:

• Meets schizophrenia criteria
• Duration 1-6 months (not 6+ months)
• Many progress to schizophrenia; some recover fully

Bipolar disorder with psychosis:

• Psychotic symptoms during mood episodes
• Mood symptoms prominent
• Familial bipolar pattern common
• Different treatment approach (mood stabilizers)

Schizoaffective disorder:

• Psychotic symptoms plus mood disorder
• Mood symptoms persist independent of psychosis
• Requires both antipsychotic and mood treatment

Delusional disorder:

• Non-bizarre delusions without other psychotic symptoms
• Rare
• Different prognosis and treatment

Medical causes of psychosis:

• Encephalitis or meningitis
• Systemic lupus erythematosus
• Thyroid dysfunction
• B12 deficiency
• Seizure disorder
• Brain tumor or stroke
• Alcohol withdrawal
• Physical examination and labs essential to exclude

First-Episode Psychosis Treatment Strategy

Initial Stabilization Phase

Goals:

• Rapid symptom control
• Ensure safety
• Reduce distress
• Begin medication

Hospitalization decision:

• Indicated if: Danger to self/others, unable to care for self, family unable to manage
• Crisis stabilization unit alternative if available
• Outpatient management possible in some cases with intensive support

Medication initiation:

• Start low, go slow: Lower doses, gradual titration
• Monotherapy preferred: Single antipsychotic reduces side effects
• Monitoring intensive: Weekly to biweekly initially
• Allow adequate time: 6-8 weeks at therapeutic dose before full assessment
• Typical timeline:
• Week 1: Start at low dose (risperidone 1-2 mg, olanzapine 5 mg, quetiapine 100 mg)
• Weeks 1-4: Gradual titration to therapeutic dose
• Weeks 4-8: Assess response at therapeutic dose
• If inadequate response: Continue optimization vs. trial antipsychotic change

Stabilization Phase (Weeks 2-8)

Assessment each visit:

• Psychotic symptom improvement
• Side effects
• Medication adherence
• Mood and safety
• Functioning

Typical response pattern:

• Week 1-2: Agitation, anxiety may improve (sedative effect)
• Week 2-4: Sleep improving, distress decreasing
• Week 4-8: Positive symptoms gradually resolving
• Hallucinations often improving by week 2-4
• Delusions take longer (4-8 weeks for meaningful improvement)
• Negative symptoms may not improve as quickly

Side effect management:

• Anticholinergic for extrapyramidal effects (if needed)
• Metformin for metabolic protection
• Dietary counseling for weight management
• Benztropine only short-term (not long-term)

Continuation Phase (Months 2-6)

Focus: Consolidating gains, supporting adjustment

Goals:

• Maintain medication compliance
• Continue symptom improvement
• Address residual symptoms
• Functional recovery initiation
• Family education and support
• Relapse prevention planning

Assessment:

• Monthly visits initially
• Psychotic symptoms monitoring
• Side effect monitoring
• Weight and metabolic parameters
• Substance use (relapse risk)
• Medication adherence barriers

Interventions:

• Psychoeducation: Patient and family
• Relapse prevention planning: Warning signs, crisis plan
• Social/vocational assessment
• Peer support groups
• Family psychoeducation groups

Maintenance Phase (After 6 Months)

Goals:

• Maintain stable remission
• Support functioning and quality of life
• Prevent relapse
• Optimize long-term prognosis

Assessment:

• Every 3-6 months typically
• Ongoing monitoring for relapse signs
• Periodic metabolic assessment
• Medication compliance assessment
• Functional/social goals progress

Long-term medication:

• Continuation essential
• Even symptomatically well, relapse risk if discontinued
• Research: 2-3 year continuation typical after first episode
• Duration individualized

Medication Management Details

Dosing Principles

First-episode approach:

• Start lower than maintenance dose
• Slower titration than chronic patients
• Goal: Maximum efficacy, minimum side effects
• First-episode usually more sensitive to treatment

Example first-episode dosing:

Risperidone:

• Day 1-3: 0.5 mg daily
• Day 4-7: 1 mg daily
• Week 2: 1.5-2 mg daily
• Week 3: 2-3 mg daily
• Maintenance: 4-6 mg daily (sometimes lower effective in first episode)

Olanzapine:

• Day 1-3: 2.5-5 mg daily
• Week 1: 5-10 mg daily
• Week 2-3: 10-15 mg daily
• Maintenance: 10-20 mg daily

Quetiapine:

• Day 1: 50 mg daily
• Day 2: 100 mg daily
• Day 3: 200 mg daily (or increase slower)
• Maintenance: 400-600 mg daily (divided)

Aripiprazole:

• Day 1-3: 5 mg daily
• Day 4-7: 10 mg daily
• Week 2+: 10-15 mg daily
• Maintenance: 10-15 mg daily (sometimes higher needed)

Monitoring During Medication Optimization

Week 1-2:

• Tolerability assessment
• Side effects
• Adherence check
• Psychiatric symptoms

Week 4:

• PANSS or symptom scale reassessment
• Metabolic panel if high-risk medication
• Weight
• Side effect management

Week 8:

• Full reassessment
• Response adequate? (20-30% improvement minimum expected)
• Side effect burden acceptable?
• Medication adjustment needed?

If inadequate response at 8 weeks:

• Ensure adequate dose and adequate duration
• Check medication adherence
• Consider second antipsychotic trial
• Add-on strategies (rarely needed first-episode)

Metabolic Monitoring Protocol

Baseline (before medication):

• Weight, BMI, waist circumference
• Fasting glucose or HbA1c
• Lipid panel
• Blood pressure
• Prolactin (optional)

During titration phase:

• Weight at each visit
• Fasting glucose 4 weeks in
• Lipids 8-12 weeks in

Maintenance:

• Weight, BMI monthly first 6 months, then quarterly
• Glucose and lipids every 3 months first year, then annually
• Prolactin if symptoms suggest elevation

Side Effect Management

Extrapyramidal side effects (EPS):

• Acute dystonia: Benztropine 1 mg IM/IV acutely
• Akathisia: Beta blocker (propranolol 20-40 mg), reduce antipsychotic, or switch agent
• Parkinsonism: Benztropine 1-2 mg daily or trihexyphenidyl 2-5 mg daily
• Tardive dyskinesia: No good treatment; prevention through judicious use, lowest effective doses

Metabolic effects:

• Weight gain: Dietary counseling, exercise, consider metformin
• Hyperglycemia: Dietary modification, weight management, consider switching agent
• Dyslipidemia: Statins if needed, lifestyle modification

Sexual/Reproductive:

• Prolactin-induced: If severe, switch to prolactin-sparing agent (aripiprazole, lurasidone)
• Erectile dysfunction: Phosphodiesterase inhibitor (viagra) or agent switch
• Irregular menses: Address prolactin elevation

Sedation:

• Take dose at night
• Allow tolerance period (often improves)
• Reduce dose if unbearable
• Switch to more activating agent (aripiprazole)

Long-Term Maintenance

Medication Continuation

Research shows:

• Relapse rates with discontinuation: 50-80% within 2 years
• Relapse rates on medication: 10-20% within 2 years
• Recommendation: Continue 2-3 years minimum after first episode
• Some require: Indefinite continuation (recurrent episodes, chronic course)

Relapse Warning Signs

Educate patient/family to recognize:

• Sleep disruption
• Increased suspiciousness
• Social withdrawal
• Difficulty concentrating
• Neglect of self-care
• Changes in speech pattern
• Mood changes
• Returning hallucinations
• Substance use

Response: Contact psychiatrist immediately; may need:

• Medication adjustment
• Temporary increased visits
• Hospitalization if needed

Psychosocial Support Continuation

Medication alone insufficient. Ongoing:

• Therapy/counseling
• Peer support groups
• Vocational/educational rehabilitation
• Family involvement and support
• Substance use monitoring/treatment if needed

KwikPsych First-Episode and Maintenance Care

At KwikPsych in Austin, Dr. Monika Thangada, MD provides:

• Rapid first-episode psychosis evaluation
• Evidence-based medication initiation and monitoring
• Intensive follow-up during stabilization
• Comprehensive medication management
• Psychoeducation and family involvement
• Coordination with psychosocial services
• Long-term maintenance care
• Crisis support

Contact KwikPsych:

• Phone: 737-367-1230
• Location: 12335 Hymeadow Dr, Ste 450, Austin, TX 78750
• Telehealth throughout Texas
• Insurance: Aetna, BCBS, Cigna, UHC, Superior/Ambetter, BSW, Oscar, First Health, Optum, Medicare
• Self-pay: $299 initial, $179 follow-up

Crisis: 988 Lifeline

Early intervention transforms outcomes. Contact us immediately if you or a loved one is experiencing psychotic symptoms.